Forbes J M & Co. LLP Has $319,000 Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT)

Forbes J M & Co. LLP raised its stake in Nuvectis Pharma, Inc. (NASDAQ:NVCT) by 21.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,000 shares of the company’s stock after acquiring an additional 10,599 shares during the quarter. Forbes J M & Co. LLP owned about 0.31% of Nuvectis Pharma worth $319,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of NVCT. Baldwin Wealth Partners LLC MA raised its position in Nuvectis Pharma by 104.4% in the 4th quarter. Baldwin Wealth Partners LLC MA now owns 355,961 shares of the company’s stock worth $1,926,000 after purchasing an additional 181,831 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Nuvectis Pharma by 49.8% during the third quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock worth $501,000 after acquiring an additional 26,489 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Nuvectis Pharma by 20.7% during the second quarter. Renaissance Technologies LLC now owns 74,500 shares of the company’s stock valued at $472,000 after acquiring an additional 12,800 shares during the period. Nations Financial Group Inc. IA ADV bought a new position in Nuvectis Pharma in the third quarter valued at about $63,000. Finally, GSA Capital Partners LLP boosted its holdings in Nuvectis Pharma by 3.7% in the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock valued at $315,000 after acquiring an additional 1,790 shares during the last quarter. 96.77% of the stock is currently owned by institutional investors and hedge funds.

Nuvectis Pharma Price Performance

Shares of NASDAQ:NVCT opened at $6.71 on Friday. Nuvectis Pharma, Inc. has a 1-year low of $4.44 and a 1-year high of $12.10. The business has a 50-day moving average price of $5.57 and a two-hundred day moving average price of $6.35.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. During the same quarter in the prior year, the company earned ($0.37) EPS. On average, equities research analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current year.

Insider Buying and Selling at Nuvectis Pharma

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri acquired 17,000 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were acquired at an average price of $4.70 per share, for a total transaction of $79,900.00. Following the acquisition, the insider now directly owns 2,612,000 shares of the company’s stock, valued at approximately $12,276,400. This trade represents a 0.66 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Ron Bentsur bought 20,000 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were acquired at an average cost of $4.92 per share, with a total value of $98,400.00. Following the completion of the purchase, the chief executive officer now owns 3,266,424 shares in the company, valued at $16,070,806.08. This represents a 0.62 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 43,500 shares of company stock worth $209,205. Insiders own 35.78% of the company’s stock.

Nuvectis Pharma Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.